Supernus and Indivior Agree to $2.2B Merger of Equals in CNS Medicine

Companies: Supernus Pharmaceuticals & Indivior Pharmaceuticals · Event Type: Merger of Equals (All-Stock) · Combined Annual Revenue: ~$2.2 Billion · Ownership Split: 56.5% Indivior / 43.5% Supernus · Expected Close: Q4 2026 Summary Supernus Pharmaceuticals and Indivior Pharmaceuticals have entered a definitive all-stock merger agreement…